Aptevo Therapeutics Shares Move Higher; Co. And Alligator Bioscience Announce Interim Data From Dose Escalation Phase Of Phase 1 ALG.APV-527 Trial Will Be Presented At ESMO Congress 2024 On Sept. 14
Portfolio Pulse from Benzinga Newsdesk
Aptevo Therapeutics and Alligator Bioscience announced that interim data from their Phase 1 ALG.APV-527 trial will be presented at the ESMO Congress 2024. This news has led to an increase in Aptevo Therapeutics' share price.
September 13, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptevo Therapeutics' shares increased following the announcement that interim data from their Phase 1 ALG.APV-527 trial will be presented at the ESMO Congress 2024.
The announcement of interim data presentation at a major congress like ESMO is a positive development, indicating progress in their clinical trial. This has likely led to increased investor confidence, driving the share price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90